2024
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression
Asch R, Abdallah C, Carson R, Esterlis I. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression. Neuropsychopharmacology 2024, 50: 153-163. PMID: 39039139, PMCID: PMC11525584, DOI: 10.1038/s41386-024-01913-3.Peer-Reviewed Original ResearchStudies of depressionAnimal models of chronic stressPositron emission tomographyModel of chronic stressSV2A imagingSynaptic densitySignificant depressive symptomsDevelopment of novel radiotracersDepressive symptomsNeuropsychiatric disordersSymptom severityChronic stressDrug challengeSynaptic vesicle glycoprotein 2 ANeural markersAnimal modelsSynaptic alterationsSynaptogenesis in vivoPreliminary findingsIn vivo quantificationCentral nervous systemDepressionEmission tomographySV2ASV2A positron emission tomography
2021
Lower synaptic density is associated with psychiatric and cognitive alterations in obesity
Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, Pietrzak RH, Esterlis I. Lower synaptic density is associated with psychiatric and cognitive alterations in obesity. Neuropsychopharmacology 2021, 47: 543-552. PMID: 34294874, PMCID: PMC8674236, DOI: 10.1038/s41386-021-01111-5.Peer-Reviewed Original ResearchConceptsStress-related psychiatric disordersBody mass indexLower synaptic densitySynaptic densityPsychiatric disordersPsychiatric diagnosisOverweight/obesityNormal-weight individualsNormal-weight participantsSerious medical conditionPositron emission tomographyStress-related psychopathologyDorsolateral prefrontal cortexOverweight/Mass indexWeight participantsWeight individualsHealthy controlsTension/anxietyAssociated symptomatologyMedical conditionsIntervention development effortsObesityCognitive alterationsPsychiatric groups